Literature DB >> 21439454

Complementary and alternative medicine and multiple sclerosis.

Allen C Bowling1.   

Abstract

Complementary and alternative medicine (CAM) is used by one-half to three-fourths of multiple sclerosis (MS) patients. Although it is used widely, CAM may not be discussed during a conventional medical visit. In MS, CAM therapies exhibit a broad range of risk-benefit profiles; some of these therapies are low risk and possibly beneficial, whereas others are ineffective, dangerous, or unstudied. Health professionals who provide objective and practical information about the risks and benefits of CAM therapies may improve the quality of care for those with MS.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Year:  2011        PMID： 21439454     DOI： 10.1016/j.ncl.2010.12.006

Source DB:  PubMed          Journal:  Neurol Clin        ISSN： 0733-8619            Impact factor:   3.806


  11 in total

1.  Exclusive use of alternative medicine as a positive choice: a qualitative study of treatment assumptions among people with multiple sclerosis in denmark.

Authors:  Lasse Skovgaard; Inge Kryger Pedersen; Marja Verhoef
Journal:  Int J MS Care       Date:  2014

2.  Phase II Randomized Controlled Trial of Constraint-Induced Movement Therapy in Multiple Sclerosis. Part 2: Effect on White Matter Integrity.

Authors:  Ameen Barghi; Jane B Allendorfer; Edward Taub; Brent Womble; Jarrod M Hicks; Gitendra Uswatte; Jerzy P Szaflarski; Victor W Mark
Journal:  Neurorehabil Neural Repair       Date:  2018-03       Impact factor: 3.919

Review 3.  Complementary and alternative therapies in multiple sclerosis: a systematic literature classification and analysis.

Authors:  Goli Arji; Hossein Rezaeizadeh; Abdolrreza Naser Moghadasi; Mohammad Ali Sahraian; Mehrdad Karimi; Mojtaba Alizadeh
Journal:  Acta Neurol Belg       Date:  2022-01-21       Impact factor: 2.396

Review 4.  Pharmacological Alternatives for the Treatment of Neurodegenerative Disorders: Wasp and Bee Venoms and Their Components as New Neuroactive Tools.

Authors:  Juliana Silva; Victoria Monge-Fuentes; Flávia Gomes; Kamila Lopes; Lilian dos Anjos; Gabriel Campos; Claudia Arenas; Andréia Biolchi; Jacqueline Gonçalves; Priscilla Galante; Leandro Campos; Márcia Mortari
Journal:  Toxins (Basel)       Date:  2015-08-18       Impact factor: 4.546

5.  The effect of omega-3 fatty acids on central nervous system remyelination in fat-1 mice.

Authors:  Elise Siegert; Friedemann Paul; Michael Rothe; Karsten H Weylandt
Journal:  BMC Neurosci       Date:  2017-01-24       Impact factor: 3.288

6.  The Liberation Procedure Decision-Making Experience for People With Multiple Sclerosis.

Authors:  Cynthia L Murray; Michelle Ploughman; Chelsea Harris; Stephen Hogan; Michelle Murdoch; Mark Stefanelli
Journal:  Glob Qual Nurs Res       Date:  2014-10-08

7.  Guided Imagery Improves Mood, Fatigue, and Quality of Life in Individuals With Multiple Sclerosis: An Exploratory Efficacy Trial of Healing Light Guided Imagery.

Authors:  Laura K Case; Paula Jackson; Revere Kinkel; Paul J Mills
Journal:  J Evid Based Integr Med       Date:  2018 Jan-Dec

8.  Use of Complementary and Alternative Medicine among People with Multiple Sclerosis in the Nordic Countries.

Authors:  L Skovgaard; P H Nicolajsen; E Pedersen; M Kant; S Fredrikson; M Verhoef; D W Meyrowitsch
Journal:  Autoimmune Dis       Date:  2012-12-11

9.  Use of bodily sensations as a risk assessment tool: exploring people with Multiple Sclerosis' views on risks of negative interactions between herbal medicine and conventional drug therapies.

Authors:  Lasse Skovgaard; Inge Kryger Pedersen; Marja Verhoef
Journal:  BMC Complement Altern Med       Date:  2014-02-18       Impact factor: 3.659

10.  Navigating the "liberation procedure": a qualitative study of motivating and hesitating factors among people with multiple sclerosis.

Authors:  Michelle Ploughman; Chelsea Harris; Stephen H Hogan; Cynthia Murray; Michelle Murdoch; Mark W Austin; Mark Stefanelli
Journal:  Patient Prefer Adherence       Date:  2014-09-10       Impact factor: 2.711
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.